alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
J. 

2 

SUPREME COURT 

OF 

NEVADA 

(0) 1947A 

Tn7,,,INNETIMINIEW-717111111 

court because these claims challenged the conditions of confinement. 

Bowen v. Warden,100 Nev. 489, 686 P.2d 250 (1984). Accordingly, we 

ORDER the judgment of the district court AFFIRMED. 

1-ku.cliesty 

Parraguirre 

cc: Hon. Gary Fairman, District Judge 

Armond Lewis 

Attorney General/Carson City 

Attorney General/Ely 

White Pine County Clerk
EXHIBIT 23.1

                          INDEPENDENT AUDITORS' CONSENT

We consent to the incorporation by reference in this  Registration  Statement on
Form S-8  pertaining  to the Elcotel,  Inc. 1991 Stock Option Plan of our report
dated June 20, 2000 (which report expresses an unqualified  opinion and includes
an  explanatory  paragraph  relating to the  Company's  ability to continue as a
going concern) appearing in the Annual Report on Form 10-K of Elcotel,  Inc. and
subsidiaries for the year ended March 31, 2000.

DELOITTE & TOUCHE LLP

Tampa, Florida
November 14, 2000
EXHIBIT 32



CERTIFICATION PURSUANT TO

18
U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Annual Report on Form 10-K/A of SportsLine.com, Inc. (the Company) for the year ended December 31, 2002, as filed with the Securities and Exchange Commission on the date hereof (the
Report), we, Michael Levy and Kenneth W. Sanders, Chief Executive Officer and Chief Financial Officer, respectively, of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act
of 2002, that to our knowledge:



(1) The
Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.



Dated November 19, 2003



|                       
|-----------------------
|/s/    Michael
Levy    
|Michael Levy           
|Chief Executive Officer



|                         
|-------------------------
|/s/    Kenneth W.
Sanders
|Kenneth W. Sanders       
|Chief Financial Officer  



A signed original of this written
statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to
SportsLine.com, Inc. and will be retained by SportsLine.com, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
<PAGE>   1



                                                                    EXHIBIT 23.1



                          INDEPENDENT AUDITORS' CONSENT



The Board of Directors
Harbinger Corporation:



We consent to incorporation by reference in the registration statements (No.
333-61893), (No. 333-30219), (No. 333-96774), (No. 333-42959) and (No.
333-03247) on Form S-8 of Harbinger Corporation of our report dated February 10,
2000, relating to the consolidated balance sheets of Harbinger Corporation as of
December 31, 1999 and 1998, and the related consolidated statements of
operations, comprehensive income (loss), shareholders' equity, and cash flows
for each of the years in the three-year period ended December 31, 1999, and the
related financial statement schedule, which report appear in the 1999 Annual
Report on Form 10-K of Harbinger Corporation.




                                  /s/ KPMG LLP


Atlanta, Georgia
March 28, 2000
# C_2015381EN.01005805.xml

| 16.11.2015 | EN | Official Journal of the European Union | C 381/58 |
| --- | --- | --- | --- |

16.11.2015

EN

Official Journal of the European Union

C 381/58

---

Order of the General Court of 8 September 2015 — Chemo Ibérica v OHIM — Novartis (EXELTIS)

(Case T-253/14) (1)

1

(2015/C 381/74)

Language of the case: Spanish

The President of the Seventh Chamber has ordered that the case be removed from the register.

---

(1)  OJ C 253, 4.8.2014.

1

---
Exhibit 13.1

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Deutsche Telekom AG (the Company), does hereby
certify, to such officers knowledge, that:

The Annual Report on Form 20-F for the year ended December 31, 2007 (the
Form 20-F), of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and information contained in the Form 20-F fairly presents, in all material respects, the
financial condition and results of operations of the Company.



|                         |  |  |  |                                                
|------------------------ |  |  |  | -----------------------------------------------
|Date: February 28, 2008  |  |  |  | /s/ René Obermann                              
|                         |  |  |  | René Obermann                                  
|                         |  |  |  | Chairman of the Management Board               
|                         |  | 
|                         |  |  |  |                                                
|Dated: February 28, 2008 |  |  |  | /s/ Dr. Karl-Gerhard Eick                      
|                         |  |  |  | Dr. Karl-Gerhard Eick                          
|                         |  |  |  | Deputy Chairman of the Management Board Finance
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JUN-30-1999
<PERIOD-START>                             JUL-01-1998
<PERIOD-END>                               SEP-30-1998
<CASH>                                      16,458,216
<SECURITIES>                                         0
<RECEIVABLES>                                1,024,426
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            17,482,642
<PP&E>                                       1,201,434
<DEPRECIATION>                                (70,463)
<TOTAL-ASSETS>                              18,613,613
<CURRENT-LIABILITIES>                           88,869
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        51,559
<OTHER-SE>                                  18,473,185
<TOTAL-LIABILITY-AND-EQUITY>                18,613,613
<SALES>                                              0
<TOTAL-REVENUES>                               261,965
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                               991,124
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              (729,159)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          (729,159)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (729,159)
<EPS-PRIMARY>                                    (.03)
<EPS-DILUTED>                                    (.03)
        

</TABLE>
Editorial Note on Part 14
Editorial Note: Nomenclature changes to part 14 appear at 88 FR 45065, July 14, 2023.

§ 14.82 Nominations of voting members of standing advisory committees. ( a ) The Commissioner will publish one or more notices in the Federal Register each year requesting nominations for voting members of all existing standing advisory committees. The notice will invite the submission of nominations for voting members from both individuals and organizations.
( b ) The notice announcing the establishment of a new committee under § 14.40(b) will invite the submission of nominations for voting members.
( c ) A person may nominate one or more qualified persons to an advisory committee. Nominations will specify the advisory committee for which the nominee is recommended and will include a complete curriculum vitae of the nominee. Nominations are to state that the nominee is aware of the nomination, is willing to serve as a member of the advisory committee, and appears to have no conflict of interest that would preclude membership.
( d ) Voting members serve as individuals and not as representatives of any group or organization which nominated them or with which they may be affiliated.
§ 522.1156 Imidocarb solution. ( a ) *Specifications.* Each milliliter of solution contains 120 milligrams (mg) of imidocarb dipropionate.
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer 6.6 mg per kilogram (3 mg per pound) of body weight by intramuscular or subcutaneous injection. Repeat the dose after 2 weeks for a total of two treatments.
( 2 ) *Indications for use.* For the treatment of clinical signs of babesiosis and/or demonstrated *Babesia* organisms in the blood.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16190, Mar. 25, 2014, as amended at 87 FR 10969, Feb. 28, 2022]
Exhibit 4.5

Form of Standard MTIP 2004 and 2005 Invitation  Letter to Current Members of  Management Board

Dear
Sir (Member of the Management Board),

Beginning
in fiscal year 2004, Deutsche Telekom AG will introduce a market based Mid-Term Incentive Plan (MTIP) as part of a competitive total compensation package. As a
global, group-wide compensation instrument, this plan will replace the 2001 Stock Option Plan. The conditions of the individual plans, each with a respective measurement period of three
years, is expected to follow annually during the next five years. The Company will decide separately on any respective new conditions and allotment amounts each year.

I
am pleased to inform you that you may participate in the first/second tranche of the MTIP.

The
first/second tranche begins on January 1, 2004/2005 (the plan end is December 31, 2006/2007) and will be based on two measures of success, one of which is absolute and
the other of which is relative. Your maximum obtainable incentive amount is EUR            .

The
first half of this maximum amount will be reached if there is an increase in the Deutsche Telekom share price of at least 30 percent at the end of the plan. The second half
will be payable, if the total return of the Deutsche Telekom share outperforms the DJ EURO STOXX Total Return Index at the end of the plan. The benchmark for the assessment will be based on the last
20 trading days before the start and at the end of the 2004/2005 Plan.

The
payment of the incentive amount of the first/second tranche will follow in the first quarter of 2007/2008 if one or both of the success parameters is reached. The basis for
participation in the program is contained in the Terms & Conditions, which are currently being prepared.

I
am convinced that we have created a market based financial incentive for your responsibility in the company and a challenge to the realization of our ambitious goals. Through these
actions, the company will ultimately be positioned to face future challenges in the market.

I
wish you all possible success in the company and look forward to continued cooperation.

Sincerely
yours,

This
translation is for convenience purposes only. The German version shall prevail.

---



QuickLinks
§ 700.14 Use of vinyl chloride as an ingredient, including propellant of cosmetic aerosol products. ( a ) Vinyl chloride has been used as an ingredient in cosmetic aerosol products including hair sprays. Where such aerosol products are used in the confines of a small room, as is often the case, the level of vinyl chloride to which the individual may be exposed could be significantly in excess of the safe level established in connection with occupational exposure. Evidence indicates that vinyl chloride inhalation can result in acute toxicity, manifested by dizziness, headache, disorientation, and unconsciousness where inhaled at high concentrations. Studies also demonstrate carcinogenic effects in animals as a result of inhalation exposure to vinyl chloride. Furthermore, vinyl chloride has recently been linked to liver disease, including liver cancer, in workers engaged in the polymerization of vinyl chloride. It is the view of the Commissioner that vinyl chloride is a deleterious substance which may render any cosmetic aerosol product that contains it as an ingredient injurious to users. Accordingly, any cosmetic aerosol product containing vinyl chloride as an ingredient is deemed to be adulterated under section 601(a) of the Federal Food, Drug, and Cosmetic Act.
( b ) Any cosmetic aerosol product containing vinyl chloride as an ingredient shipped within the jurisdiction of the Act is subject to regulatory action.
[39 FR 30830, Aug. 26, 1974]
# C_2014212EN.01004701.xml

| 7.7.2014 | EN | Official Journal of the European Union | C 212/47 |
| --- | --- | --- | --- |

7.7.2014

EN

Official Journal of the European Union

C 212/47

---

Action brought on 20 May 2014 — ZZ v Commission

(Case F-46/14)

2014/C 212/61

Language of the case: French

Parties

Parties

Applicant: ZZ (represented by: J.-N. Louis, lawyer)

Applicant:

Defendant: European Commission

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

Annulment of the decision concerning the transfer of the applicant’s pension rights to the European Union pension scheme applying the new GIP on Articles 11 and 12 of Annex VIII to the Staff Regulations

Form of order sought

Form of order sought

| — | Annul the decision of 8 November 2013 calculating the bonus to his pension rights acquired before his entry into service in the Commission; |
| --- | --- |

—

Annul the decision of 8 November 2013 calculating the bonus to his pension rights acquired before his entry into service in the Commission;

| — | Order the Commission to pay the costs. |
| --- | --- |

—

Order the Commission to pay the costs.

---
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Federal Maritime Commission

Notice is hereby given that the following applicants have filed with the Federal Maritime Commission an application for license as a Non-Vessel-Operating Common Carrier and Ocean Freight Forwarder—Ocean Transportation Intermediary pursuant to section 19 of the Shipping Act of 1984 as amended (46 U.S.C. Chapter 409 and 46 CFR part 515).

Persons knowing of any reason why the following applicants  should not receive a license are requested to contact the Office  of Transportation Intermediaries, Federal Maritime Commission, Washington, DC 20573.

Non-Vessel-Operating Common Carrier—Ocean Transportation Intermediary

Intlmove LLC, 16980 NE. 19th Avenue, North Miami Beach, FL 33162. Officers: Eric J. Polacek, President/Member, David Etzion, Member, (Qualifying Individuals), Gloria Comins, Member.

Lars Courier, Inc. dba Lars International Freight  Forwarders, 16900 North Bay Road, Apt. 1906, Sunny Isles, FL 33160. Officers: Rudy O. Vargas-Milian, Secretary, (Qualifying Individual), Andres Panesso, President/Treasurer/Director.

Non-Vessel-Operating Common Carrier and Ocean Freight Forwarder Transportation Intermediary Applicants

Intertrans Express (NY), Inc., 10 East Merrick Road, #203, Valley Stream, NY 11580. Officer: Chun aka Peter T. Tao, President/Secretary, (Qualifying Individual).

International Trade Brokers and Forwarders Co, 2261 NW. 66th Avenue, #221, Miami, FL 33122. Officer: Alvaro Munoz, President, (Qualifying Individual).

T & B Master Logistics, Inc., 4919 Indian Wood Road, Suite 399, Culver City, CA 90230. Officers: Sunnie Kim, Secretary, (Qualifying Individual), Hyeon S. Shin, President/CEO/Treasurer/CFO.

Ocean Freight Forwarder—Ocean Transportation Intermediary Applicants

Dandino, Inc. dba Relo Moving, 626 E. 62nd Street, Los Angeles, CA 90001. Officers: Carlos Gonzales, Vice President, (Qualifying Individual), Daniel Yaniv, President.

Dated: February 26, 2010.

Rachel E. Dickon,

Assistant Secretary. 

[FR Doc. 2010-4419 Filed 3-2-10; 8:45 am]

BILLING CODE 6730-01-P
<TABLE> <S> <C>

<ARTICLE>                                 5
<LEGEND>
     This schedule  contains summary  financial  information  extracted from the
Partnership's  audited  financial  statements for the quarter ended December 31,
1995 and is qualified in its entirety by reference to such financial statements.
</LEGEND>
<MULTIPLIER>                                   1,000
       
<S>                                         <C>
<PERIOD-TYPE>                             9-MOS
<FISCAL-YEAR-END>                         MAR-31-1996
<PERIOD-END>                              DEC-31-1995
<CASH>                                         3,143
<SECURITIES>                                       0
<RECEIVABLES>                                     81
<ALLOWANCES>                                     (1)
<INVENTORY>                                        0
<CURRENT-ASSETS>                               3,246
<PP&E>                                        33,919
<DEPRECIATION>                                 3,278
<TOTAL-ASSETS>                                34,168
<CURRENT-LIABILITIES>                            408
<BONDS>                                       11,068
<COMMON>                                           0
<PREFERRED-MANDATORY>                              0
<PREFERRED>                                        0
<OTHER-SE>                                    22,692
<TOTAL-LIABILITY-AND-EQUITY>                  34,168
<SALES>                                            0
<TOTAL-REVENUES>                               2,509
<CGS>                                              0
<TOTAL-COSTS>                                  1,098
<OTHER-EXPENSES>                                   0
<LOSS-PROVISION>                                   0
<INTEREST-EXPENSE>                             1,376
<INCOME-PRETAX>                                   35
<INCOME-TAX>                                       0
<INCOME-CONTINUING>                               35
<DISCONTINUED>                                     0
<EXTRAORDINARY>                                    0
<CHANGES>                                          0
<NET-INCOME>                                      35
<EPS-PRIMARY>                                   0.69
<EPS-DILUTED>                                   0.69
        


</TABLE>
# C_2015056EN.01002002.xml

| 16.2.2015 | EN | Official Journal of the European Union | C 56/20 |
| --- | --- | --- | --- |

16.2.2015

EN

Official Journal of the European Union

C 56/20

---

Order of the General Court of 10 December 2014 — Mabrouk v Council

(Case T-277/14) (1)

1

((Common foreign and security policy - Restrictive measures directed against certain persons and entities in view of the situation in Tunisia - Freezing of funds - Action for failure to act - Request for access to the evidence used by the Council against a natural person affected by those measures - Access granted by the Council - Action becoming devoid of purpose - No need to adjudicate))

(2015/C 056/28)

Language of the case: English

Parties

Parties

Applicant: Mohamed Marouen Ben Ali Ben Mohamed Mabrouk (Tunis, Tunisia) (represented by: J.-R. Farthouat, J.-P. Mignard, N. Boulay, lawyers and S. Crosby, Solicitor)

Applicant:

Defendant: Council of the European Union (represented by: A. De Elera and G. Étienne, acting as Agents)

Defendant:

Re:

Re:

Action seeking a declaration of a failure to act on the part of the Council in that it unlawfully failed to act upon the applicant’s request for access to the file containing the evidence on which the Council relied in ordering the freezing of his assets in the European Union.

Operative part of the order

Operative part of the order

| 1. | There is no need to adjudicate on the action. |
| --- | --- |

1.

There is no need to adjudicate on the action.

| 2. | The Council of the European Union shall pay the costs. |
| --- | --- |

2.

The Council of the European Union shall pay the costs.

---

(1)  OJ C 194, 24.6.2014.

1

---
§ 522.2424 Thiamylal. ( a ) *Specifications.* The drug is a sterile powder. It is reconstituted with sterile distilled water, water for injection, or sodium chloride injection, to a desired concentration of 0.5 to 4 percent sodium thiamylal.
( b ) *Sponsors.* See Nos. 054771 and 069043 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* Administer by intravenous injection to effect. The average single dose is: ( i ) *Dogs and cats:* 8 milligrams (mg) per pound of body weight (when used with a preanesthetic, generally one-half the normal dose).
( ii ) *Swine:* 40 mg per 5 pounds (lbs) of body weight.
( iii ) *Horses:* Light anesthesia, 1 gram per 500 lbs to 1,100 lbs of body weight; deep anethesia, 1 gram per 300 lbs of body weight (40 mg/12 lbs of body weight).
( iv ) *Cattle:* Short duration, 20 mg/5 lbs of body weight; longer duration, 40 mg/7 lbs of body weight.
( 2 ) *Indications for use.* It is used as an ultra-short-acting anesthetic in dogs, cats, swine, horses, and cattle.
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16196, Mar. 25, 2014, as amended at 83 FR 48946, Sept. 28, 2018]
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.2920 Plasma viscometer for clinical use. ( a ) *Identification.* A plasma viscometer for clinical use is a device intended to measure the viscosity of plasma by determining the time period required for the plasma to flow a measured distance through a calibrated glass tube. Measurements obtained by this device are used to monitor changes in the amount of solids present in plasma in various disorders.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
[52 FR 16122, May 1, 1987, as amended at 60 FR 38900, July 28, 1995; 66 FR 38788, July 25, 2001]